Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH
- PMID: 15851425
- PMCID: PMC1720405
- DOI: 10.1136/adc.2002.024463
Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH
Abstract
Background: Gaviscon Infant (GI) has been recommended for gastro-oesophageal reflux (GOR) in infants. Its efficacy has not been examined with a physiologically appropriate denominator to define the degree of GOR.
Aim: To investigate the influence of Gaviscon Infant on GOR in infants using combined pH and intraluminal impedance measurement.
Methods: Twenty infants (mean age 163.5 days, range 34-319 days) exclusively bottle fed, with symptoms clinically suggestive of GOR, underwent 24 hour studies of intra-oesophageal 6 channel impedance and dual channel pH monitoring, during which six random administrations (3+3) of Gaviscon Infant (625 mg in 225 ml milk) or placebo (mannitol and Solvito N, 625 mg in 225 ml milk) were given in a double blind fashion. Impedance/pH reflux data were recorded and analysed blind by one observer.
Results: The median number of reflux events/hour (1.58 v 1.68), acid reflux events/hour (0.26 v 0.43), minimum distal or proximal pH, total acid clearance time per hour (time with pH below pH 4), and total reflux duration per hour were not significantly different after GI than after placebo. Reflux height was marginally lower after GI (median 66.6% v 77.3% oesophageal length) compared with placebo.
Conclusions: Results showed a marginal but significant difference between Gaviscon Infant and placebo in average reflux height, and raises questions regarding any perceived clinical benefit of its use.
Figures
Comment in
-
Gaviscon for gastro-oesophageal reflux in infants: a poorly effective treatment?Arch Dis Child. 2006 Jan;91(1):93. doi: 10.1136/adc.2005.086355. Arch Dis Child. 2006. PMID: 16371388 Free PMC article. No abstract available.
Similar articles
-
Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.Aliment Pharmacol Ther. 2013 Jun;37(11):1093-102. doi: 10.1111/apt.12318. Epub 2013 Apr 18. Aliment Pharmacol Ther. 2013. PMID: 23600790 Clinical Trial.
-
The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants.Aliment Pharmacol Ther. 2011 Feb;33(4):466-70. doi: 10.1111/j.1365-2036.2010.04545.x. Epub 2010 Dec 15. Aliment Pharmacol Ther. 2011. PMID: 21158879 Clinical Trial.
-
Sodium Alginate (Gaviscon®) does not reduce apnoeas related to gastro-oesophageal reflux in preterm infants.Early Hum Dev. 2011 Dec;87(12):775-8. doi: 10.1016/j.earlhumdev.2011.05.013. Epub 2011 Jun 22. Early Hum Dev. 2011. PMID: 21696897 Clinical Trial.
-
Pharmacological treatment of children with gastro-oesophageal reflux.Cochrane Database Syst Rev. 2014 Nov 24;2014(11):CD008550. doi: 10.1002/14651858.CD008550.pub2. Cochrane Database Syst Rev. 2014. PMID: 25419906 Free PMC article. Review.
-
Cisapride treatment for gastro-oesophageal reflux in children.Cochrane Database Syst Rev. 2000;(3):CD002300. doi: 10.1002/14651858.CD002300. Cochrane Database Syst Rev. 2000. PMID: 10908549 Updated. Review.
Cited by
-
A Novel In Vitro Model for Determining the Optimum pH and Dose Volume of New Liquid Alginate for Infant Reflux Suppression.Drugs R D. 2021 Sep;21(3):331-339. doi: 10.1007/s40268-021-00356-1. Epub 2021 Jul 20. Drugs R D. 2021. PMID: 34283413 Free PMC article.
-
Alginates: From the ocean to gastroesophageal reflux disease treatment.Turk J Gastroenterol. 2019 Sep;30(Suppl2):109-136. doi: 10.5152/tjg.2019.19677. Turk J Gastroenterol. 2019. PMID: 31624050 Free PMC article. No abstract available.
-
Optimizing the Use of Medications and Other Therapies in Infant Gastroesophageal Reflux.Paediatr Drugs. 2018 Dec;20(6):523-537. doi: 10.1007/s40272-018-0311-3. Paediatr Drugs. 2018. PMID: 30198060 Review.
-
The Effect of Alginate in Gastroesophageal Reflux in Infants.Paediatr Drugs. 2018 Dec;20(6):575-583. doi: 10.1007/s40272-018-0314-0. Paediatr Drugs. 2018. PMID: 30182358 Free PMC article.
-
Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.J Pediatr Gastroenterol Nutr. 2018 Mar;66(3):516-554. doi: 10.1097/MPG.0000000000001889. J Pediatr Gastroenterol Nutr. 2018. PMID: 29470322 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical